FIELD: biotechnology.
SUBSTANCE: invention allows for the production of a mutant polypeptide linker developed from a hinge IgG1 sequence with remote glycosylation sites. The specified linker can be used in the production of different multi-specific antibodies.
EFFECT: compared to known analogues, the use of a linker according to the present invention allows for the production of more uniform preparations of multi-specific antibodies.
20 cl, 5 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| ANTIGEN-BINDING PROTEINS AGAINST GITR AND METHODS OF THEIR USE | 2017 |
|
RU2795625C2 |
| PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
